A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.

Vena, G A

A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. [electronic resource] - International journal of immunopathology and pharmacology - 227-33 p. digital

Publication Type: Journal Article; Multicenter Study

0394-6320

10.1177/039463200902200125 doi


Adalimumab
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Psoriasis--drug therapy
Tumor Necrosis Factor-alpha--antagonists & inhibitors